SARS-CoV-2 vaccines in patients with SLE

As the Moderna (mRNA-1273) and Pfizer/BioNTech (BNT162b2) vaccines become available to patients with autoimmune diseases and SLE, practitioners will have to inform them about the safety and efficacy of these vaccines. Here we discuss the challenges of applying vaccine data to patients with autoimmun...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Wei, Askanase, Anca D, Khalili, Leila, Merrill, Joan T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941677/
https://www.ncbi.nlm.nih.gov/pubmed/33685998
http://dx.doi.org/10.1136/lupus-2021-000479
Descripción
Sumario:As the Moderna (mRNA-1273) and Pfizer/BioNTech (BNT162b2) vaccines become available to patients with autoimmune diseases and SLE, practitioners will have to inform them about the safety and efficacy of these vaccines. Here we discuss the challenges of applying vaccine data to patients with autoimmune diseases and the evidence available in the literature that may help in the decision process.

Ejemplares similares